Vanderbilt University Medical Center
2200 Children's Way
Nashville, TN 37232
Vanderbilt University Medical Center is one of twenty-two type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Bill Russell, MD, the TrialNet team at Vanderbilt is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.
Bill Russell, MD
Faith Brendle, RN, CPN, CCRP
Anne Brown, MSN, BC-ANP, BC-ADM
Brenna Hammel, BSN, RN, CPN
Kim Rainer, RN
The following studies are actively recruiting participants. Please click on the study title to learn more. For those interested in participation, contact us for more information.
If you have a relative with T1D, you may be eligible for risk screening that can detect the early stages of T1D years before symptoms appear. More
Depending on your risk screening results, you may be eligible for monitoring. We’ll monitor you for disease progression and let you know if you become eligible for a study. More
We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D. Details
TrialNet tested the drug abatacept to see if it could delay or prevent stage 1 T1D (two or more diabetes-related autoantibodies, but normal blood sugar) from progressing to stage 2 (abnormal blood sugar) or to stage 3 (clinical diagnosis). In an earlier study in people newly diagnosed (stage 3), participants treated with abatacept had 59% better insulin production and a 9.6-month average delay in progression of insulin loss compared to those who received placebo. That difference extended out to 3 years. Details
If you are diagnosed with T1D while participating in one of our prevention studies, we’re still here for you. You can continue to receive personal monitoring while helping us learn more. More